Merrill keeps Alexion at buy

Alexion Pharmaceuticals Inc. was maintained at a buy rating by Merrill Lynch analyst David Munno on the company's third-quarter "non-event." Alexion continues to make significant progress toward commercialization of Soliris, with Food and Drug Administration and EMEA approvals possible in late March. Munno adjusted revenue and expense estimates for the Soliris launch. Shares of the Cheshire, Conn.-based biotechnology company were up $1.21, or 3.24%, at $38.57. (Nasdaq: ALXN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.